News Forget Merck, now Pfizer is said to be after Seagen Rumour of negotiations comes as Pfizer is facing a steep patent cliff in the next few years.
News J&J gets restricted label for PARP drug Akeega in EU Drug is backed for BRCA+ prostate cancer patients only, a narrower group than rival Lynparza.
News Redx joins with Jounce to create cancer, fibrosis biotech Merger is announced after Jounce said it will slash staff and seek partners for its programmes.
News Actinium radioligand aces AML trial as filings beckon Survival doubled when Iomab-B was used as a conditioning regimen before a stem cell transplant.
News Daiichi Sankyo wins round in Enhertu patent dispute US PTO has agreed to take another look at whether Seagen's '039 patent is valid.
News Lynparza under siege in first-line prostate cancer New data from Pfizer and J&J encroach on AZ and Merck's territory with the PARP inhibitor.
News CMS aims for broader GLP-1 access via federal programmes CMS has revealed a new, voluntary access programme that aims to broaden the use of GLP-1 agonist medicines for diabetes and obesity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
